Merck KGaA, Darmstadt, Germany Intensifies Research Initiatives to Fight Schistosomiasis
- Pediatric Praziquantel Consortium starts pivotal Phase III study for a pediatric praziquantel formulation in Kenya
- Neglected tropical disease schistosomiasis affects almost 240 million people worldwide and causes about 200,000 deaths per year
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that, as part of its integrated Schistosomiasis Elimination Program, it is intensifying its Research & Development (R&D) efforts to develop and provide access to transformative and sustainable health solutions to fight schistosomiasis. As one of the flagship projects, the Pediatric Praziquantel Consortium program initiated the Phase III clinical trial in Kenya for a new formulation of praziquantel to treat schistosomiasis in pre-school age children (<6 years of age). This trial will also be conducted in Ivory Coast.
“As a leading company in the fight against schistosomiasis, Merck KGaA, Darmstadt, Germany wants to impactfully contribute to the control and elimination of the disease through sustainable innovation development,” said Petra Wicklandt, Head of Corporate Affairs at Merck KGaA, Darmstadt, Germany. “The Pediatric Praziquantel Consortium program has made remarkable progress. The start of the Phase III trial, which I witnessed by visiting the clinical site in Homa Bay in Kenya, is just one example of recent achievements.”
“The availability of a pediatric medication is essential to address the medical need of infected preschool-age children. Our investment today will secure our future generation,” said Dr. Maurice Odiere, Principal Investigator for the pediatric formulation Phase III trial and Principal Research Officer at the Kenya Medical Research Institute (KEMRI).
Through its Global Health Institute, Merck KGaA, Darmstadt, Germany has established a portfolio of innovative and collaborative projects for new or adapted treatments, sensitive schistosomiasis diagnostics, technologies to control transmission, and educational approaches to strengthen health systems in low- and middle-income countries.
Together with partners, Merck KGaA, Darmstadt, Germany is performing drug discovery activities for new treatments. Promising assets from Salvensis and the London School of Hygiene & Tropical Medicine have recently been obtained to identify potential new candidates to prevent and cure patients affected by schistosomiasis. In addition, the company is collaborating with the Foundation for Innovative New Diagnostics (FIND) and the Bill & Melinda Gates Foundation to develop a Rapid Diagnostic Test as a new sensitive diagnostic to improve mapping and case detection for schistosomiasis. Furthermore, Merck KGaA, Darmstadt, Germany is investing into innovative technologies for vector control and clean water to control transmission. The recently announced Eisai / Merck KGaA, Darmstadt, Germany partnership addresses this topic.
Merck KGaA, Darmstadt, Germany complements these R&D activities with its annual donation of up to 250 million praziquantel tablets, the standard-of-care treatment, to the World Health Organization (WHO). The neglected tropical disease schistosomiasis affects almost 240 million people worldwide, mainly in communities without access to safe drinking water and with poor sanitation, with an estimated number of deaths of about 200,000 per year.
Schistosomiasis (also known as bilharzia) is one of the most prevalent parasitic diseases in sub-Saharan Africa, caused by parasitic flatworms called schistosomes. It affects almost 240 million people, mainly in communities without access to safe drinking water and with poor sanitation, with an estimated number of deaths of about 200,000 per year. The parasites live within freshwater snails and infect humans by penetrating the skin. The disease can lead to chronic inflammation of the organs, which can be fatal but also to anaemia, stunted growth and impaired learning ability with devastating consequences for the lives of the young children.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Related NewsView All News
Merck KGaA, Darmstadt, Germany will present data from a Phase II placebo-controlled randomized trial at the 2021 American Academy of Neurology (AAN) Annual Meeting.